Body Mass Index and Breast Cancer Risk: A Retrospective Multi-Institutional Analysis in Saudi Arabia

Volker Rudat, Nuha Birido, Saleh Tuwaijri, Mousa A. Al-Abbadi

Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital, Dammam, KSA.
Department of Radiation Oncology, Saad Specialist Hospital, Al Khobar, KSA.
Department of Surgery, King Fahad Specialist Hospital, Dammam, KSA.
Saad Research & Development Center, Saad Specialist Hospital, Al Khobar, KSA.

DOI: 10.4236/abcr.2013.21002                

Abstract

Background: The purpose of this study was to evaluate the association between the body mass index (BMI) of breast cancer patients and non-cancer females of the Eastern Province of Saudi Arabia. Methods: The weight, height and age was obtained from the patient records of 706 newly diagnosed breast cancer patients and of 20,872 non-cancer female patients who consulted the two largest hospitals in the Eastern Province of Saudi Arabia between 2006 and 2012. Factorial analysis of variance (ANOVA) was used to assess the association between the BMI, age and breast cancer status. Results: The mean BMI of the non-cancer females was 29.4 and the percentage of obese patients of the different age groups ranged from 23.9% to 66.5%. The BMI increased significantly with age. The ANOVA revealed that breast cancer patients older than 50 years had a significantly lower BMI compared to their non-cancer counterparts (p = 0.01). Conclusion: Our data confirm the high BMI of the Saudi Arabian female population. The reason for our finding of a lower BMI of postmenopausal breast cancer patients compared to their non-cancer counterparts is unclear. Future studies are warranted to assess the impact of possible confounding factors on the association between obesity and breast cancer risk. An interesting factor to investigate in future studies would particularly be the use of the anti-diabetic and cancer-protective drug metformin considering that diabetes mellitus is endemic in Saudi Arabia with a prevalence of 30%.

Keywords

Breast Cancer; Body Mass Index; Adolescent; Female; Saudi Arabia

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	B. M. Popkin, “Understanding Global Nutrition Dynamics as a Step towards Controlling Cancer Incidence,” Nature Reviews Cancer, Vol. 7, No. 1, 2007, pp. 61-67. doi:10.1038/nrc2029
[2]	E. E. Calle and R. Kaaks, “Overweight, Obesity and Cancer: Epidemiological Evidence and Proposed Mechanisms,” Nature Reviews Cancer, Vol. 4, No. 8, 2004, pp. 579-591. doi:10.1038/nrc1408
[3]	A. R. Carmichael, “Obesity and Prognosis of Breast Cancer,” Obesity Reviews, Vol. 7, No. 4, 2006, pp. 333-340. doi:10.1111/j.1467-789X.2006.00261.x
[4]	M. Protani, M. Coory and J. H. Martin, “Effect of Obesity on Survival of Women with Breast Cancer: Systematic Review and Meta-Analysis,” Breast Cancer Research and Treatment, Vol. 123, No. 3, 2010, pp. 627-635. doi:10.1007/s10549-010-0990-0
[5]	National Cancer Institute, “Surveillance, Epidemiology and End Results (SEER) Program,” 2012. http://seer.cancer.gov/statfacts/html/breast.html#incidence-mortality
[6]	H. S. Al-Eid, “Cancer Incidence and Survival Report Saudi Arabia 2007,” 2012. http://www.scr.org.sa/reports/SCR2007.pdf
[7]	V. Rudat, I. Brune-Erbe, A. Noureldin, Z. Bushnag, N. Almuraikhi and S. Altuwaijri, “Epidemiology of Breast Cancer Patients at a Tertiary Care Center in the Eastern Province of Saudi Arabia,” Gulf Journal of Oncology, Vol. 1, No. 11, 2012, pp. 45-49.
[8]	V. Rudat, H. El-Sweilmeen, E. Fadel, I. Brune-Erber, A. A. Nour, Z. Bushnag, N. Masri and S. Altuwaijri, “Age of 40 Years or Younger Is an Independent Risk Factor for Locoregional Failure in Early Breast Cancer: A Single-Institutional Analysis in Saudi Arabia,” Journal of Oncology, Vol. 2012, 2012, p. 370385.
[9]	C. K. Anders, R. Johnson, J. Litton, M. Phillips and A. Bleyer, “Breast Cancer before Age 40 Years,” Seminars in Oncology, Vol. 36, No. 3, 2009, pp. 237-249. doi:10.1053/j.seminoncol.2009.03.001
[10]	K. M. Flegal, M. D. Carroll, B. K. Kit and C. L. Ogden, “Prevalence of Obesity and Trends in the Distribution of Body Mass Index among US Adults, 1999-2010,” JAMA, Vol. 307, No. 5, 2012, pp. 491-497. doi:10.1001/jama.2012.39
[11]	A. R. Carmichael and T. Bates, “Obesity and Breast Cancer: A Review of the Literature,” Breast, Vol. 13, No. 2, 2004, pp. 85-92. doi:10.1016/j.breast.2003.03.001
[12]	S. Loi, R. L. Milne, M. L. Friedlander, M. R. E. McCredie, G. G. Giles, J. L. Hopper and K.-A. Phillips, “Obesity and Outcomes in Premenopausal and Postmenopausal Breast Cancer,” Cancer Epidemiology Biomarkers & Prevention, Vol. 14, No. 7, 2005, pp. 1686-1691. doi:10.1158/1055-9965.EPI-05-0042
[13]	N. A. Al-Baghli, A. J. Al-Ghamdi, K. A. Al-Turki, A. G. El-Zubaier, M. M. Al-Ameer and F. A. Al-Baghli, “Overweight and Obesity in the Eastern Province of Saudi Arabia,” Saudi Medical Journal, Vol. 29, No. 9, 2008, pp. 1319-1325.
[14]	M. M. Al-Nozha, Y. Y. Al-Mazrou, M. A. Al-Maatouq, M. R. Arafah, M. Z. Khalil, N. B. Khan, K. Al-Marzouki, M. A. Abdullah, A. H. Al-Khadra, S. S. Al-Harthi, et al., “Obesity in Saudi Arabia,” Saudi Medical Journal, Vol. 26, No. 5, 2005, pp. 824-829.
[15]	H. S. Feigelson, C. R. Jonas, L. R. Teras, M. J. Thun and E. E. Calle, “Weight Gain, Body Mass Index, Hormone Replacement Therapy, and Postmenopausal Breast Cancer in a Large Prospective Study,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 13, No. 2, 2004, pp. 220-224. doi:10.1158/1055-9965.EPI-03-0301
[16]	C. Schairer, J. Lubin, R. Troisi, S. Sturgeon, L. Brinton and R. Hoover, “Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk,” JAMA, Vol. 283, No. 4, 2000, pp. 485-491. doi:10.1001/jama.283.4.485
[17]	Collaborative Group on Hormonal Factors in Breast Cancer, “Breast Cancer and Hormone Replacement Therapy: Collaborative Reanalysis of Data from 51 Epidemiological Studies of 52,705 Women with Breast Cancer and 108,411 Women without Breast Cancer,” Lancet, Vol. 350, No. 9084, 1997, pp. 1047-1059. doi:10.1016/S0140-6736(97)08233-0
[18]	L. M. Morimoto, E. White, Z. Chen, R. T. Chlebowski, J. Hays, L. Kuller, A. M. Lopez, J. Manson, K. L. Margolis, P. C. Muti, et al., “Obesity, Body Size, and Risk of Postmenopausal Breast Cancer: The Women’s Health Initiative (United States),” Cancer Causes Control, Vol. 13, No. 8, 2002, pp. 741-751. doi:10.1023/A:1020239211145
[19]	S. C. Larsson, C. S. Mantzoros and A. Wolk, “Diabetes Mellitus and Risk of Breast Cancer: A Meta-Analysis,” International Journal of Cancer, Vol. 121, No. 4, 2007, pp. 856-862. doi:10.1002/ijc.22717
[20]	L. Vona-Davis and D. P. Rose, “Type 2 Diabetes and Obesity Metabolic Interactions: Common Factors for Breast Cancer Risk and Novel Approaches to Prevention and Therapy,” Current Diabetes Reviews, Vol. 8, No. 2, 2012, pp. 116-130. doi:10.2174/157339912799424519
[21]	K. S. Peairs, B. B. Barone, C. F. Snyder, H. C. Yeh, K. B. Stein, R. L. Derr, F. L. Brancati and A. C. Wolff, “Dia- betes Mellitus and Breast Cancer Outcomes: A Systematic Review and Meta-Analysis,” Journal of Clinical Oncology, Vol. 29, No. 1, 2011, pp. 40-46. doi:10.1200/JCO.2009.27.3011
[22]	M. E. Del Giudice, I. G. Fantus, S. Ezzat, G. McKeown-Eyssen, D. Page and P. J. Goodwin, “Insulin and Related Factors in Premenopausal Breast Cancer Risk,” Breast Cancer Research and Treatment, Vol. 47, No. 2, 1998, pp. 111-120. doi:10.1023/A:1005831013718
[23]	I. Wolf, S. Sadetzki, R. Catane, A. Karasik and B. Kaufman, “Diabetes Mellitus and Breast Cancer,” The Lancet Oncology, Vol. 6, No. 2, 2005, pp. 103-111. doi:10.1016/S1470-2045(05)01736-5
[24]	K. Erickson, R. E. Patterson, S. W. Flatt, L. Natarajan, B. A. Parker, D. D. Heath, G. A. Laughlin, N. Saquib, C. L. Rock and J. P. Pierce, “Clinically Defined Type 2 Diabetes Mellitus and Prognosis in Early-Stage Breast Cancer,” Journal of Clinical Oncology, Vol. 29, No. 1, 2011, pp. 54-60. doi:10.1200/JCO.2010.29.3183
[25]	D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin and B. Zinman, “Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetes Care, Vol. 32, No. 1, 2009, pp. 193-203. doi:10.2337/dc08-9025
[26]	R. T. Chlebowski, A. McTiernan, J. Wactawski-Wende, J. E. Manson, A. K. Aragaki, T. Rohan, E. Ipp, V. G. Kaklamani, M. Vitolins, R. Wallace, et al., “Diabetes, Metformin, and Breast Cancer in Postmenopausal Women,” Journal of Clinical Oncology, Vol. 30, No. 23, 2012, pp. 2844-2852. doi:10.1200/JCO.2011.39.7505
[27]	H. Noto, A. Goto, T. Tsujimoto and M. Noda, “Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-Analysis,” PLoS One, Vol. 7, No. 3, 2012, p. e33411. doi:10.1371/journal.pone.0033411
[28]	N. F. Col, L. Ochs, V. Springmann, A. K. Aragaki and R. T. Chlebowski, “Metformin and Breast Cancer Risk: A Meta-Analysis and Critical Literature Review,” Breast Cancer Research and Treatment, Vol. 135, No. 3, 2012, pp. 639-646. doi:10.1007/s10549-012-2170-x
[29]	K. A. Alqurashi, K. S. Aljabri and S. A. Bokhari, “Prevalence of Diabetes Mellitus in a Saudi Community,” Annals of Saudi Medicine, Vol. 31, No. 1, 2011, pp. 19-23. doi:10.4103/0256-4947.75773